Trial Profile
Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Carfilzomib (Primary) ; Copanlisib (Primary) ; Daratumumab (Primary) ; Fludeoxyglucose F-18 (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Obinutuzumab (Primary) ; Pembrolizumab (Primary) ; Rituximab (Primary) ; Romidepsin (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cutaneous T-cell lymphoma; Hodgkin's disease; Mycosis fungoides; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 22 May 2023 Planned End Date changed from 1 May 2023 to 1 May 2026.
- 22 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2025.
- 13 Mar 2023 Status changed from recruiting to suspended because of funding - sponsor filing of Chapter 11 bankruptcy.